Plasma brain natriuretic peptide is associated with hepatic veno-occlusive disease and early mortality after allogeneic hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 45, Issue 11, 2010, Pages 1631-1637

  Kataoka, K ^a,b   Nannya, Y ^a   Iwata, H ^a   Seo, S ^a   Kumano, K ^a,c   Takahashi, T ^a   Nagai, R ^a   Kurokawa, M ^a,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^c UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

brain natriuretic peptide; hematopoietic stem cell transplantation; hepatic veno occlusive disease; prognosis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADOLESCENT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENGRAFTMENT; FEMALE; FLUID RETENTION; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER VEIN OBSTRUCTION; MALE; MORTALITY; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 78149465909     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.26     Document Type: Article

References (32)

1. Kumar S, DeLeve LD, Kamath PS, Tefferi A. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc 2003; 78: 589-598. (Pubitemid 36529900)
2. Wadleigh M, Ho V, Momtaz P, Richardson P. Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. Curr Opin Hematol 2003; 10: 451-462. (Pubitemid 37352490)
3. Coppell JA, Brown SA, Perry DJ. Veno-occlusive disease: cytokines, genetics, and haemostasis. Blood Rev 2003; 17: 63-70.
4. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316-322. (Pubitemid 36936846)
5. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis ofheart failure. N Engl J Med 2002; 347: 161-167. (Pubitemid 34764819)
6. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350: 647-654. (Pubitemid 38364623)
7. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014-1021.
8. Niwa N, Watanabe E, Hamaguchi M, Kodera Y, Miyazaki H, Kodama I et al. Early and late elevation of plasma atrial and brain natriuretic peptides in patients after bone marrow transplantation. Ann Hematol 2001; 80: 460-465. (Pubitemid 32771608)
9. Takatsuka H, Nakajima T, Nomura K, Okikawa Y, Wakae T, Toda A et al. Prognosis value of atrial natriuretic peptide and brain natriuretic peptide for heart failure in patients under-going allogeneic bone marrow transplantation. Hematology 2006; 11: 351-354. (Pubitemid 46957658)
10. Masuko M, Ito M, Kurasaki T, Yano T, Takizawa J, Toba K et al. Plasma brain natriuretic peptide during myeloablative stem cell transplantation. Intern Med 2007; 46: 551-555. (Pubitemid 46845844)
11. Snowden JA, Hill GR, Hunt P, Carnoutsos S, Spearing RL, Espiner E et al. Assessment of cardiotoxicity during haemo-poietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant 2000; 26: 309-313. (Pubitemid 30614412)
12. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC: Lyon, 2008.
13. Tichelli A, Bhatia S, Socie G. Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. Br J Haematol 2008; 142: 11-26. (Pubitemid 351784478)
14. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-1655.
15. Hingorani SR, Guthrie K, Batchelder A, Schoch G, Aboulhosn N, Manchion J et al. Acute renal failure after myeloablative hemato-poietic cell transplant: incidence and risk factors. Kidney Int 2005; 67: 272-277. (Pubitemid 40019249)
16. Przepiorka D, WeisdorfD, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
17. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267. (Pubitemid 23046384)
18. Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002; 100: 4337-4343. (Pubitemid 35429671)
19. Akiba T, Tachibana K, Togashi K, Hiroe M, Marumo F. Plasma human brain natriuretic peptide in chronic renal failure. Clin Nephrol 1995; 44 (Suppl 1): S61-S64.
20. McCullough PA, Sandberg KR. B-type natriuretic peptide and renal disease. Heart Fail Rev 2003; 8: 355-358. (Pubitemid 37548056)
21. Maeder M, Fehr T, Rickli H, Ammann P. Sepsis-associated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest 2006; 129: 1349-1366.
22. Brueckmann M, Huhle G, Lang S, Haase KK, Bertsch T, Weiss C et al. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 2005; 112: 527-534. (Pubitemid 41060793)
23. Charpentier J, Luyt CE, Fulla Y, Vinsonneau C, Cariou A, Grabar S et al. Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004; 32: 660-665. (Pubitemid 38340060)
24. McLean AS, Huang SJ, Hyams S, Poh G, Nalos M, Pandit R et al. Prognostic values of B-type natriuretic peptide in severe sepsis and septic shock. Crit Care Med 2007; 35: 1019-1026. (Pubitemid 46598950)
25. Bybee KA, Prasad A. Stress-related cardiomyopathy syn-dromes. Circulation 2008; 118: 397-409.
26. Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998; 92: 737-744. (Pubitemid 28355454)
27. Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11: 1729-1736. (Pubitemid 23277325)
28. Bruneau BG, de Bold AJ. Selective changes in natriuretic peptide and early response gene expression in isolated rat atria following stimulation by stretch or endothelin-1. Cardiovasc Res 1994; 28: 1519-1525.
29. Bruneau BG, Piazza LA, de Bold AJ. BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria. Am J Physiol 1997; 273 (6 Part 2): H2678-H2686. (Pubitemid 127752054)
30. Ma KK, Ogawa T, de Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by proinflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol 2004; 36: 505-513. (Pubitemid 38469941)
31. Henriksen JH, Gotze JP, Fuglsang S, Christensen E, Bendtsen F, Moller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003; 52: 1511-1517. (Pubitemid 37176734)
32. Sagnella GA. Practical implications of current natriuretic peptide research. J Renin Angiotensin Aldosterone Syst 2000; 1: 304-315.